# Efficacy and Safety of Cadonilimab and Chemoradiotherapy in Unresectable Locally Advanced Esophageal Squamous Cell Carcinoma

> **NCT06715501** · NA · ENROLLING_BY_INVITATION · sponsor: **First Affiliated Hospital of Ningbo University** · enrollment: 20 (estimated)

## Conditions studied

- Locally Advanced Esophageal Squamous Cell Carcinoma
- II-IIIB Stages

## Interventions

- **DRUG:** Cadonilimab
- **RADIATION:** radiotherapy
- **DRUG:** carboplatin, paclitaxel

## Key facts

- **NCT ID:** NCT06715501
- **Lead sponsor:** First Affiliated Hospital of Ningbo University
- **Sponsor class:** NETWORK
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** ENROLLING_BY_INVITATION
- **Start date:** 2024-12-01
- **Primary completion:** 2025-09-01
- **Final completion:** 2027-09-01
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2025-03-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06715501

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06715501, "Efficacy and Safety of Cadonilimab and Chemoradiotherapy in Unresectable Locally Advanced Esophageal Squamous Cell Carcinoma". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT06715501. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*